Not recruiting
Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Registered drugNo placebo
Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Registered drugNo placebo
- Disease:Follicle centre lymphoma follicular grade I II - III refractory
- Substances:EpcoritamabLenalidomide+1
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:AbbVie Deutschland GmbH & Co. KG



